Similarly, miR-542-3p, a common tumor-suppresser that is also downregulated in HCC tissues and cell lines, has been shown to inhibit HCC cell growth by targeting Fz7 and may thus represent a novel therapeutic target for HCC (Wu et al., 2017). Here, FZD7 is linked to neoplasm.